← Leaderboards
Ac Matin
Stanford University
$5,825,181
Attributed
$5,825,181
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $975.9K · FY2008–17$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$5,825,181 · 5
By mechanism
UH3$1,951,760 · 1
UH2$1,614,422 · 1
R01$985,035 · 1
P50$886,671 · 1
R21$387,293 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Thomas None Quertermous$63,279,401
- Thomas C Sudhof$47,983,108
- Anshul Kundaje$16,927,829
- Stephen Montgomery$23,593,399
- Michael Peter Fischbein$4,674,471
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorIn VivoMalignant NeoplasmsKillingsIn VitroCancer CellProdrugsDosePropertyEnzymesBaseReceptorCell KillingDrug KineticsCollaborationsToxic EffectPhenoxazineLife&AposImmunocompromised HostLigandsRegimenLaboratoriesAntigens
Grant awards (17)
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$975,880
UH3 · FY2017 · TR · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$975,880
UH3 · FY2016 · TR · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$476,899
UH2 · FY2015 · TR · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$79,037
UH2 · FY2015 · TR · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$488,674
UH2 · FY2014 · TR · contact PI
Developmental Funds$196,434
P50 · FY2014 · CA · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$71,042
UH2 · FY2014 · TR · contact PI
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy$498,770
UH2 · FY2013 · TR · contact PI
Developmental Funds$183,229
P50 · FY2013 · CA · contact PI
Developmental Funds$147,250
P50 · FY2012 · CA · contact PI
Developmental Funds$163,517
P50 · FY2011 · CA · contact PI
Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy$328,364
R01 · FY2010 · CA · contact PI
Development of Contrast Agents from Bacterial Magnetite for Targeting and Visuali$211,248
R21 · FY2010 · CA · contact PI
Developmental Funds$196,241
P50 · FY2010 · CA · contact PI
Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy$328,345
R01 · FY2009 · CA · contact PI
Development of Contrast Agents from Bacterial Magnetite for Targeting and Visuali$176,045
R21 · FY2009 · CA · contact PI
Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy$328,326
R01 · FY2008 · CA · contact PI